{"id":35102,"date":"2026-04-28T17:49:00","date_gmt":"2026-04-28T12:19:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35102"},"modified":"2026-04-28T15:50:08","modified_gmt":"2026-04-28T10:20:08","slug":"pharma-news-for-eli-lilly-sun-pharma-novartis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis","title":{"rendered":"Eli Lilly and Company to Acquire Ajax Therapeutics; Sun Pharma Moves to Acquire Organon in Definitive Agreement; European Commission Approves Novartis RHAPSIDO as First Oral Targeted Therapy for Chronic Spontaneous Urticaria; Tovecimig Delivers Significant Clinical Benefit in COMPANION-002 Phase 2\/3 Trial for Biliary Tract Cancer; Arrowhead Pharmaceuticals Receives CHMP Backing for REDEMPLO Approval in Europe for Familial Chylomicronemia Syndrome"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f0ef578017f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f0ef578017f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis\/#Eli_Lilly_and_Company_Signs_Deal_to_Acquire_Ajax_Therapeutics\" >Eli Lilly and Company Signs Deal to Acquire Ajax Therapeutics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis\/#Sun_Pharma_Announces_Definitive_Agreement_for_Acquisition_of_Organon\" >Sun Pharma Announces Definitive Agreement for Acquisition of Organon<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis\/#Novartiss_RHAPSIDO_Gains_European_Commission_Approval_as_First_Oral_Targeted_Therapy_for_Chronic_Spontaneous_Urticaria\" >Novartis\u2019s RHAPSIDO Gains European Commission Approval as First Oral Targeted Therapy for Chronic Spontaneous Urticaria<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis\/#Tovecimig_Achieves_Statistically_Significant_Benefit_in_COMPANION-002_Phase_23_Trial_for_Biliary_Tract_Cancer\" >Tovecimig Achieves Statistically Significant Benefit in COMPANION-002 Phase 2\/3 Trial for Biliary Tract Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis\/#Arrowhead_Pharmaceuticals_Secures_Positive_CHMP_Opinion_for_REDEMPLO_in_Adults_with_Familial_Chylomicronemia_Syndrome_in_Europe\" >Arrowhead Pharmaceuticals Secures Positive CHMP Opinion for REDEMPLO in Adults with Familial Chylomicronemia Syndrome in Europe<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-eli-lilly-and-company-signs-deal-to-acquire-ajax-therapeutics\"><span class=\"ez-toc-section\" id=\"Eli_Lilly_and_Company_Signs_Deal_to_Acquire_Ajax_Therapeutics\"><\/span>Eli Lilly and Company Signs Deal to Acquire Ajax Therapeutics<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Eli Lilly and Company <\/strong>has entered into a definitive agreement to acquire <strong>Ajax Therapeutics, Inc.<\/strong>, a biotechnology firm specializing in next-generation JAK inhibitors for myeloproliferative neoplasms (MPNs). The deal is structured with a total potential value of <strong>$2.3 billion<\/strong>, consisting of an upfront cash payment followed by milestone-based payouts linked to clinical and regulatory success. This acquisition centers on Ajax\u2019s primary asset, <strong>AJ1-11095<\/strong>, a first-in-class, once-daily oral <a href=\"https:\/\/www.delveinsight.com\/report-store\/janus-kinase-jak-inhibitors-market\"><strong>Type II JAK2 inhibitor<\/strong><\/a>. The drug is currently undergoing a Phase 1 clinical trial (AJX-101) involving patients with myelofibrosis who have previously been treated with traditional Type I JAK2 inhibitors.<\/p>\n\n\n\n<p>The strategic rationale behind the acquisition lies in the limitations of current MPN treatments. Existing approved therapies utilize a Type I binding mechanism, which, while effective for symptomatic relief, often fails to provide long-term durability, leading many patients to discontinue treatment. AJ1-11095 is specifically engineered to bind to the Type II conformation, aiming to provide deeper efficacy and a viable alternative for those who develop resistance to standard therapies.<\/p>\n\n\n\n<p>Lilly, an early strategic investor in Ajax, intends to leverage its extensive hematology expertise to accelerate the drug&#8217;s development. Following the expected selection of an optimal dose in 2026, Lilly plans to move the asset into registrational trials. The transaction remains subject to customary closing conditions and antitrust clearance under the <strong>Hart-Scott-Rodino Act<\/strong>. Legal counsel for the deal includes Ropes &amp; Gray LLP for Lilly and Cooley LLP, along with Kirkland &amp; Ellis LLP for Ajax.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sun-pharma-announces-definitive-agreement-for-acquisition-of-organon\"><span class=\"ez-toc-section\" id=\"Sun_Pharma_Announces_Definitive_Agreement_for_Acquisition_of_Organon\"><\/span>Sun Pharma Announces Definitive Agreement for Acquisition of Organon<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Sun Pharmaceutical Industries Ltd. and Organon &amp; Co.<\/strong> have entered into a definitive agreement for Sun Pharma to acquire all outstanding shares of Organon for <strong>$14.00 per share<\/strong> in an all-cash deal. The transaction carries an enterprise valuation of approximately <strong>$11.75 billion<\/strong>, representing a significant <strong>103%<\/strong> premium over Organon\u2019s recent unaffected share price. This strategic merger is poised to transform Sun Pharma into a top 25 global pharmaceutical entity with combined annual revenues exceeding<strong> $12.4 billion<\/strong>.<\/p>\n\n\n\n<p>Organon, originally a spinoff from Merck (MSD), brings a robust portfolio of over 70 products across Women\u2019s Health and General Medicines, including a growing biosimilars franchise. By integrating Organon\u2019s global reach, spanning 140 countries and supported by six manufacturing facilities, Sun Pharma will become a dominant player in established brands and the third-largest company in the global Women\u2019s Health sector. The acquisition aligns with Sun Pharma\u2019s strategy to shift toward innovative medicines and high-value branded generics while doubling its cash flow and EBITDA. The deal has received unanimous approval from both boards and is expected to close in early 2027. This combination creates a diversified platform for future product launches and commercial expansion, particularly in major markets like the U.S., Europe, and China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novartis-s-rhapsido-gains-european-commission-approval-as-first-oral-targeted-therapy-for-chronic-spontaneous-urticaria\"><span class=\"ez-toc-section\" id=\"Novartiss_RHAPSIDO_Gains_European_Commission_Approval_as_First_Oral_Targeted_Therapy_for_Chronic_Spontaneous_Urticaria\"><\/span>Novartis\u2019s RHAPSIDO Gains European Commission Approval as First Oral Targeted Therapy for Chronic Spontaneous Urticaria<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Novartis<\/strong> has officially announced that the <strong>European Commission (EC)<\/strong> has approved <strong>Rhapsido (remibrutinib)<\/strong> for the treatment of adult patients suffering from <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-spontaneous-urticaria-market\">chronic spontaneous urticaria (CSU)<\/a>. This approval is specifically for those who have not achieved adequate symptom control through standard H1-antihistamine treatments. Notably, Rhapsido distinguishes itself as the first oral targeted therapy for CSU, providing patients with a convenient twice-daily pill that does not necessitate routine laboratory monitoring.<\/p>\n\n\n\n<p>The medical community has welcomed the decision, as CSU is characterized by debilitating itch, swelling, and unpredictable flares that severely disrupt sleep, productivity, and emotional health. By blocking a critical immune pathway, Rhapsido offers rapid relief and significant disease control. This regulatory milestone follows a positive recommendation from the <strong>Committee for Medicinal Products for Human Use (CHMP)<\/strong> in February 2026. Furthermore, the treatment has already been integrated into the <strong>2026 International Guideline<\/strong> for the management of urticaria.<\/p>\n\n\n\n<p>Novartis views this approval as a pivotal step in expanding its immunology portfolio. Beyond CSU, the company is investigating the potential of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/btk-inhibitors-market-forecast\">Bruton\u2019s tyrosine kinase (BTK) inhibitor<\/a> pathway for other immune-mediated conditions, including food allergies, hidradenitis suppurativa, and chronic inducible urticaria. According to Patrick Horber, M.D., President, International at Novartis, the oral targeted approach represents a major advance in providing faster relief and improved daily disease management for a broad range of patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tovecimig-achieves-statistically-significant-benefit-in-companion-002-phase-2-3-trial-for-biliary-tract-cancer\"><span class=\"ez-toc-section\" id=\"Tovecimig_Achieves_Statistically_Significant_Benefit_in_COMPANION-002_Phase_23_Trial_for_Biliary_Tract_Cancer\"><\/span>Tovecimig Achieves Statistically Significant Benefit in COMPANION-002 Phase 2\/3 Trial for Biliary Tract Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Compass Therapeutics<\/strong> has announced positive results from the <strong>Phase 2\/3 COMPANION-002<\/strong> <strong>study<\/strong>, evaluating its lead candidate, <strong>tovecimig<\/strong>, in patients with advanced <a href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-market\">biliary tract cancer (BTC)<\/a>. Tovecimig is a bispecific antibody designed to target both DLL4 and VEGF-A. In the study, it was tested in combination with paclitaxel against paclitaxel alone for patients who had progressed after first-line therapy.<\/p>\n\n\n\n<p>The trial successfully met its primary endpoint, showing a significant improvement in the overall response rate (ORR). Specifically, the tovecimig combination achieved a 17.1% ORR compared to just 5.3% for the chemotherapy-only group. Furthermore, the secondary endpoint of progression-free survival (PFS) was also met, with the combination therapy reducing the risk of disease progression by 56%. Patients in the tovecimig arm saw a median PFS of 4.7 months, nearly doubling the 2.6 months recorded in the control group.<\/p>\n\n\n\n<p>A post-hoc analysis also indicated a substantial benefit for patients who crossed over to receive tovecimig after their disease progressed on paclitaxel alone. The safety profile remained consistent with previous data, with common side effects including hypertension and fatigue. Based on these results, Compass Therapeutics intends to discuss a potential Biologics License Application (BLA) with the FDA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-arrowhead-pharmaceuticals-secures-positive-chmp-opinion-for-redemplo-in-adults-with-familial-chylomicronemia-syndrome-in-europe\"><span class=\"ez-toc-section\" id=\"Arrowhead_Pharmaceuticals_Secures_Positive_CHMP_Opinion_for_REDEMPLO_in_Adults_with_Familial_Chylomicronemia_Syndrome_in_Europe\"><\/span>Arrowhead Pharmaceuticals Secures Positive CHMP Opinion for REDEMPLO in Adults with Familial Chylomicronemia Syndrome in Europe<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Arrowhead Pharmaceuticals, Inc. <\/strong>recently announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of <strong>REDEMPLO (plozasiran)<\/strong>. This therapy is designed as an adjunct to diet for adult patients suffering from <a href=\"https:\/\/www.delveinsight.com\/report-store\/familial-chylomicronemia-syndrome-market\">Familial Chylomicronemia Syndrome (FCS)<\/a>, a rare and severe genetic disorder. FCS is characterized by extremely high levels of triglycerides, which puts patients at a constant and life-threatening risk of acute pancreatitis.<\/p>\n\n\n\n<p>The CHMP&#8217;s recommendation is primarily supported by data from the <strong>PALISADE Phase 3 clinical trial<\/strong>. In this study, REDEMPLO demonstrated a profound ability to lower triglycerides, with patients achieving a median reduction of 80% compared to those receiving a placebo. Beyond lipid-lowering, the trial also indicated a significant decrease in the incidence of acute pancreatitis events, addressing the most dangerous complication of the disease.<\/p>\n\n\n\n<p>REDEMPLO utilizes Arrowhead\u2019s proprietary <strong>TRiM (Targeted RNAi Molecule) platform<\/strong> to deliver a first-in-class small interfering RNA (siRNA) medicine that targets the production of APOC3. It is administered via subcutaneous injection once every three months, providing a manageable long-term treatment schedule. The safety profile observed in clinical trials was generally favorable, with common adverse events including headache and nasopharyngitis. Following the CHMP\u2019s recommendation, a final marketing authorization decision from the European Commission is expected by mid-2026, which would make REDEMPLO the first RNAi-based treatment available for FCS patients in the European Union.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company Signs Deal to Acquire Ajax Therapeutics Eli Lilly and Company has entered into a definitive agreement to acquire Ajax Therapeutics, Inc., a biotechnology firm specializing in next-generation JAK inhibitors for myeloproliferative neoplasms (MPNs). The deal is structured with a total potential value of $2.3 billion, consisting of an upfront cash payment [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35104,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[16752,132,19119,15936,17510,349,639],"industry":[17225],"therapeutic_areas":[],"class_list":["post-35102","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biliary-tract-cancer","tag-btk-inhibitors","tag-chronic-spontaneous-urticaria","tag-familial-chylomicronemia-syndrome","tag-jak-inhibitor","tag-latest-pharma-news","tag-pharma-news","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Eli Lilly, Sun Pharma, Novartis<\/title>\n<meta name=\"description\" content=\"Eli Lilly\u2019s Ajax Acquisition; Sun Pharma\u2019s Organon Acquisition; Novartis\u2019s RHAPSIDO; Compass Therapeutics\u2019 Tovecimig; Arrowhead\u2019s REDEMPLO\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Eli Lilly, Sun Pharma, Novartis\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly\u2019s Ajax Acquisition; Sun Pharma\u2019s Organon Acquisition; Novartis\u2019s RHAPSIDO; Compass Therapeutics\u2019 Tovecimig; Arrowhead\u2019s REDEMPLO\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T12:19:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/04\/pharma-news-for-eli-lilly-sun-pharma-novartis.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Eli Lilly, Sun Pharma, Novartis","description":"Eli Lilly\u2019s Ajax Acquisition; Sun Pharma\u2019s Organon Acquisition; Novartis\u2019s RHAPSIDO; Compass Therapeutics\u2019 Tovecimig; Arrowhead\u2019s REDEMPLO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Eli Lilly, Sun Pharma, Novartis","og_description":"Eli Lilly\u2019s Ajax Acquisition; Sun Pharma\u2019s Organon Acquisition; Novartis\u2019s RHAPSIDO; Compass Therapeutics\u2019 Tovecimig; Arrowhead\u2019s REDEMPLO","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-04-28T12:19:00+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/04\/pharma-news-for-eli-lilly-sun-pharma-novartis.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis","name":"Pharma News | Eli Lilly, Sun Pharma, Novartis","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/04\/pharma-news-for-eli-lilly-sun-pharma-novartis.webp","datePublished":"2026-04-28T12:19:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Eli Lilly\u2019s Ajax Acquisition; Sun Pharma\u2019s Organon Acquisition; Novartis\u2019s RHAPSIDO; Compass Therapeutics\u2019 Tovecimig; Arrowhead\u2019s REDEMPLO","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-eli-lilly-sun-pharma-novartis#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/04\/pharma-news-for-eli-lilly-sun-pharma-novartis.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/04\/pharma-news-for-eli-lilly-sun-pharma-novartis.webp","width":772,"height":482,"caption":"pharma-news-for-eli-lilly-sun-pharma-novartis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/04\/pharma-news-for-eli-lilly-sun-pharma-novartis-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biliary tract cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BTK Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Familial Chylomicronemia Syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">JAK inhibitor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biliary tract cancer<\/span>","<span class=\"advgb-post-tax-term\">BTK Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Chronic Spontaneous Urticaria<\/span>","<span class=\"advgb-post-tax-term\">Familial Chylomicronemia Syndrome<\/span>","<span class=\"advgb-post-tax-term\">JAK inhibitor<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 16 minutes ago","modified":"Updated 2 hours ago"},"absolute_dates":{"created":"Posted on Apr 28, 2026","modified":"Updated on Apr 28, 2026"},"absolute_dates_time":{"created":"Posted on Apr 28, 2026 5:49 pm","modified":"Updated on Apr 28, 2026 3:50 pm"},"featured_img_caption":"pharma-news-for-eli-lilly-sun-pharma-novartis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35102"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35102\/revisions"}],"predecessor-version":[{"id":35103,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35102\/revisions\/35103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35104"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35102"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35102"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}